Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.

Authors:
Kimbara S; Kondo S.

Journal:
World J Gastroenterol

Publication Year: 2016

DOI:
10.3748/wjg.v22.i33.7440

PMCID:
PMC5011660

PMID:
27672267

View on PubMed View on PMC View Publisher
Journal Information

Full Title: World J Gastroenterol

Abbreviation: World J Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Antiviral treatment standards for hepatitis B: An urgent need for expansion.
Bao ZH; Dai ZK; Tang HX. (2024) - Transparency Score: 2/6
Automatic detection of small bowel lesions with different bleeding risks based on deep learning mod…
Zhang RY; Qiang PP; Cai LJ and 5 more (2024) - Transparency Score: 3/6
Bile acids inhibit ferroptosis sensitivity through activating farnesoid X receptor in gastric cance…
Liu CX; Gao Y; Xu XF and 10 more (2024) - Transparency Score: 3/6
Cholecystokinin and cholecystokinin-A receptor: An attractive treatment strategy for biliary dyskin…
Chang J; Liu Y; Jiang TC and 2 more (2024) - Transparency Score: 2/6
Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obe…
Li YJ; Baumert BO; Stratakis N and 20 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict-of-interest statement: Shiro Kimbara have no conflict of interest associated with this manuscript. Shunsuke Kondo received research funding from AstraZeneca, Eli Lilly and Company, and Bayer AG."

Evidence found in paper:

"Supported by JSPS Grant-in-Aid for Young Scientists (B), No. 268605371; AstraZeneca, Eli Lilly and Company, and Bayer AG (to Kondo S)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025